公开(公告)号：DE3722273A1

公开(公告)日：1988-01-21

申请号：DE3722273

申请日：1987-07-06

Applicant: BIO RAD LABORATORIES

Inventor： WALKER ROGER P ,  LAMOTTE III GEORGE B

IPC: G01N33/543 ,  G01N33/569

Abstract: Solid phase binding reagents for biochemical binding assays are prepared by isolating a plurality of selected binding species from a biological source mixture such as a cell or viral lysate; diluting each isolated species in a carrier liquid, such as a detergent-containing buffer solution, to form a series of stock mixtures each at a preselected concentration; and applying the mixtures to discrete, precisely defined regions on a solid phase support, immobilizing the species according to a preselected pattern. After suitable washing, blocking and stabilization steps, the resulting solid phase reagent may be used like a Western blot of an electropherogram, but with distinct advantages in terms of accuracy, reproducibility and readability.

公开(公告)号：CA2868952A1

公开(公告)日：2013-10-24

申请号：CA2868952

申请日：2013-03-21

Applicant: BIO RAD LABORATORIES

Inventor： BINDER STEVEN R ,  WALKER ROGER P ,  DELANOY MICHELLE L

IPC: G01N33/53

Abstract: Rheumatoid arthritis and other autoimmune diseases are diagnosed by multiplex assays for antibodies to a panel of antigens that includes cyclic citrullinated peptide and at least five members of a list that includes BRAF1 506-525, BRAF2 656-675, Vimentin (protein) citrullinated, Vimentin 415-433 cit cyclic, Vimentin 58-77 cit3 cyclic, Clusterin 231-250 cit sm1 cyclic, Fibrinogen A 556-575 cit sm cyclic, Fibrinogen A 616-635 cit sm cyclic, Histones2A H2A/a 1-20 cit sm2 cyclic, Filaggrin 48-65 cit2v1 cyclic, BRAF (catalytic domain from v raf murine sarcoma viral oncogene homologue B1, amino acids

公开(公告)号：AU3024889A

公开(公告)日：1989-10-05

申请号：AU3024889

申请日：1989-02-23

Applicant: BIO RAD LABORATORIES

Inventor： DECHENE NEAL E ,  RATHBUN BARBARA J ,  REGAN BARBARA P ,  WALKER ROGER P

IPC: G01N33/547 ,  G01N33/552 ,  G01N33/569 ,  G01N33/571

Abstract: A biospecific assay method where detection of herpesviruses using silane-derivatized solid supports is disclosed. The solid supports are silanized to produce surface aminoalkyl, alkyl, or aminophenoxy groups, whereby adsorption of herpes virus particles onto the derivatized solid support is substantially increased. The method involves disrupting a herpesvirus in a sample with a solubilization agent, immobilizing the herpesvirus so disrupted on the derivatized solid support, contacting the immobilized herpesvirus with a primary antibody specific for the disrupted virus particle to form an immunocomplex, contacting the immunocomplex with a second antibody which has a label appended thereto to form a labeled immunocomplex, and detecting the labeled immunocomplex.

公开(公告)号：AU3076189A

公开(公告)日：1989-08-31

申请号：AU3076189

申请日：1989-02-24

Applicant: BIO RAD LABORATORIES

Inventor： WALKER ROGER P ,  PAREKH BHARAT S

IPC: G01N33/569 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61P31/12 ,  C07K14/155 ,  C07K14/16 ,  C07K14/705 ,  C07K16/00 ,  C07K16/10 ,  C07K15/12 ,  C07K7/06 ,  C07K7/08 ,  C07K7/10 ,  G01N33/571 ,  G01N33/577 ,  G01N33/549 ,  A61K39/21

Abstract: Methods and compositions for HIV-1 diagnosis, treatment, and vaccination include one or more peptides which correspond to antigenic determinants encoded by conserved regions of the HIV-1 genome. The peptides will be immunologically cross-reactive with such antigenic determinant sites and, preferably, will be capable of eliciting a serum-neutralizing response when administered to an individual who may or may not be infected with HIV-1. Antibodies to such peptides will also find use in the present invention.

公开(公告)号：AU2013249767A1

公开(公告)日：2014-10-16

申请号：AU2013249767

申请日：2013-03-21

Applicant: BIO RAD LABORATORIES

Inventor： BINDER STEVEN R ,  WALKER ROGER P ,  DELANOY MICHELLE L

IPC: G01N33/53

Abstract: Rheumatoid arthritis and other autoimmune diseases are diagnosed by multiplex assays for antibodies to a panel of antigens that includes cyclic citrullinated peptide and at least five members of a list that includes BRAF1 506-525, BRAF2 656-675, Vimentin (protein) citrullinated, Vimentin 415-433 cit cyclic, Vimentin 58-77 cit3 cyclic, Clusterin 231-250 cit sm1 cyclic, Fibrinogen A 556-575 cit sm cyclic, Fibrinogen A 616-635 cit sm cyclic, Histones2A H2A/a 1-20 cit sm2 cyclic, Filaggrin 48-65 cit2v1 cyclic, BRAF (catalytic domain from v raf murine sarcoma viral oncogene homologue B1, amino acids

公开(公告)号：GB2194046A

公开(公告)日：1988-02-24

申请号：GB8716020

申请日：1987-07-08

Applicant: BIO RAD LABORATORIES

Inventor： WALKER ROGER P ,  LAMOTTE III GEORGE B

IPC: G01N33/543 ,  G01N33/569 ,  G01N33/53 ,  G01N33/531 ,  G01N33/567

公开(公告)号：AU7696487A

公开(公告)日：1988-01-29

申请号：AU7696487

申请日：1987-07-02

Applicant: BIO RAD LABORATORIES

Inventor： WALKER ROGER P ,  LAMOTTE GEORGE ,  THOMSON DAVID M P

IPC: C12N15/09 ,  C07K5/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/435 ,  C07K14/705 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  C12N15/02 ,  C12P21/02 ,  C12P21/08 ,  G01N33/574 ,  G01N33/531 ,  G01N33/554

Abstract: Methods and compositions for diagnosing and monitoring patients suffering from neoplastic diseases, such as lung cancer. Peptide fragments embodying epitopic sites characteristic of organ-specific neoantigens capable of inducing leukocyte adherence inhibition have been prepared. The peptide fragments, and antibodies prepared from the fragments, are used to detect the OSN in patient specimens, particularly serum. Presence of the neoantigen in serum samples is diagnostic of the specific cancer. Various immunological techniques can be used to detect the neoantigen in such patient specimens. Alternatively, leukocyte adherence inhibition assays can be utilized using the purified peptides.

公开(公告)号：ES2902226T3

公开(公告)日：2022-03-25

申请号：ES18749715

申请日：2018-07-19

Applicant: BIO RAD EUROPE GMBH ,  BIO RAD LABORATORIES

Inventor： BATXELLI-MOLINA ISABELLE ,  SALIPANTE FLORIAN ,  WALKER ROGER P ,  FLANAGAN JOHN ,  FAREH-MICHIEL JEANNETTE

IPC: G01N33/68

Abstract: Un procedimiento para diagnosticar la esteatohepatitis no alcohólica (NASH) y/o el estatus de fibrosis hepática de un sujeto, en el que el procedimiento comprende: (I) medir, en una muestra obtenida de un sujeto, los niveles de al menos tres biomarcadores que sean una citoquina proinflamatoria, una quimioquina y un glicosaminoglicano que contribuyan a la adhesión celular y al modelado de los tejidos; (II) combinar los niveles de dichos al menos tres biomarcadores medidos en la etapa (I) en un modelo matemático; y (III) determinar si el sujeto padece NASH y/o determinar su estatus de fibrosis hepática, dichos al menos tres biomarcadores que comprenden IL-8, CXCL10 y ácido hialurónico (HA).

公开(公告)号：FR2601454A1

公开(公告)日：1988-01-15

申请号：FR8709635

申请日：1987-07-07

Applicant: BIO RAD LABORATORIES

Inventor： WALKER ROGER P ,  LAMOTTE GEORGE B

IPC: G01N33/543 ,  G01N33/569